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In Brief
The oncometabolite D-2-
hydroxyglutarate (D-2HG) generated via
mutant isocitrate dehydrogenase
contributes to cancer pathogenesis.
Intlekofer et al. and Oldham et al. now
show that the enantiomer L-2HG is
selectively produced in hypoxic cells to
regulate histonemethylation levels and to
help mitigate cellular reductive stress
through inhibition of glycolysis and
electron transport.
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Metabolic adaptation to hypoxia is critical for sur-
vival in metazoan species for which reason they
have developed cellular mechanisms for mitigating
its adverse consequences. Here, we have identified
L-2-hydroxyglutarate (L2HG) as a universal adaptive
determinant of the hypoxia response. L2HG is a
metabolite of unknown function produced by the
reduction of mitochondrial 2-oxoglutarate by malate
dehydrogenase. L2HG accumulates in response to
increases in 2-oxoglutarate, which occur as a result
of tricarboxylic acid cycle dysfunction and increased
mitochondrial reducing potential. These changes are
closely coupled to cellular redox homeostasis, as
increased cellular L2HG inhibits electron transport
and glycolysis to offset the adverse consequences
of mitochondrial reductive stress induced by hypox-
ia. Thus, L2HG couples mitochondrial and cyto-
plasmic energy metabolism in a model of cellular
redox regulation.
INTRODUCTION
Hypoxia is an important environmental stimulus that causes ge-
netic and metabolic reprogramming in cells to facilitate survival.
This programmed response is mediated primarily through stabi-
lization of hypoxia-inducible factor 1a (HIF1a), a transcription
factor that coordinates a shift in energy metabolism away from
oxidative phosphorylation and toward glycolysis and lactate
fermentation through the increased expression of glucose trans-
porters (GLUT1), glycolytic enzymes, lactate dehydrogenase
(LDHA), and pyruvate dehydrogenase kinase (Semenza, 2012).
These changes limit carbon entry into the tricarboxylic acid cycle
(TCA) and mitigate damage from reactive oxygen species (ROS)
generated by dysfunctional (uncoupled) electron transport in the
mitochondria (Zhang et al., 2008).CelWhile hypoxia limits the proliferation of many cell types, some
cancer cells, stem/progenitor cells, and pulmonary vascular
cells continue to grow and divide in low-oxygen conditions.
Metabolic flux analyses suggest that transformed cell lines
may utilize reductive carboxylation of glutamine-derived 2-oxo-
glutarate (2OG) by isocitrate dehydrogenase (IDH) to overcome
the limitation of decreased glucose-derived citrate on macro-
molecular biosynthesis under hypoxic conditions (Gameiro
et al., 2013; Scott et al., 2011; Wise et al., 2011). However,
the overall contribution of reductive carboxylation to net re-
ductive carbon flux has been questioned (Fan et al., 2013).
Indeed, evidence for a glutamine-driven, glucose-independent
oxidative TCA cycle under hypoxic conditions has been found
in human Burkitt lymphoma cells, which would be consistent
with both oxidative and reductive flux through IDH (Le et al.,
2012). Notably, these studies have all been performed in trans-
formed cells. Comparatively little is known about the metabolic
response to hypoxia in primary cells.
Given that hypoxia is a potent stimulus of pulmonary vascular
cell remodeling and proliferation in the pathogenesis of pulmo-
nary hypertension (Cottrill and Chan, 2013), we performed
metabolic profiling of human pulmonary arterial endothelial
and smooth muscle cells (PAECs and PASMCs) exposed to
0.2% oxygen for 24 hr. This oxygen tension is below the P50
for mitochondrial respiration (Vemuri et al., 2007), which would
enhance any differences between glycolytic and oxidative
metabolism. As expected, hypoxia had a significant impact on
pathways involved in energy metabolism and precursor bio-
synthesis. Interestingly, in contrast to other TCA metabolites,
hypoxia caused a 2-fold increase in intracellular 2OG with a
concomitant increase in its reduced metabolite, 2-hydroxy-
glutarate (2HG). Two enantiomers of 2HG, L and D, have been
associated with separate, rare inborn errors of metabolism re-
sulting in increased urinary excretion of 2HG linked to neurolog-
ical deficits in children (Chalmers et al., 1980; Duran et al., 1980;
Kranendijk et al., 2012). While the roles of L2HG and D2HG in
normal human metabolism are unknown, L2HG has recently
been shown to accumulate in renal cell carcinoma (Struys,
2013) and in children and cell lines with electron transport chain
defects (Mullen et al., 2014; Reinecke et al., 2012; Worth et al.,l Metabolism 22, 291–303, August 4, 2015 ª2015 Elsevier Inc. 291
Figure 1. Hypoxia Increases 2OG and 2HG
(A) Volcano plot of metabolite changes in PASMC
treated with 0.2% oxygen for 24 hr compared to
21% oxygen controls. AA, amino acids; NA, nu-
cleic acid pathway intermediates; PPP, pentose
phosphate pathway intermediates; TCA, tricar-
boxylic acid cycle intermediates.
(B and C) Targeted LC-MS/MS reveals that hyp-
oxia-mediated increases in 2OG (B) and 2HG (C)
occur in a variety of cell types. PAEC, human
pulmonary artery endothelial cells; PASMC, hu-
man pulmonary artery smooth muscle cells; LF,
human lung fibroblasts; HEK, human embryonic
kidney 293 cells; HepG2, human liver hepatocel-
lular carcinoma cells; MSC, human mesenchymal
stem cells.
(D) Intracellular 2OG and 2HG vary inversely
with oxygen tension in PASMC (p < 0.0001 for
trend for each). Data are mean ± SEM. See also
Figure S1.2015). By contrast, D2HG has been identified as the product
of cancer-associated mutant IDH enzymes (Cairns and
Mak, 2013; Dang et al., 2009; Ward et al., 2010). Both enantio-
mers inhibit 2OG-dependent dioxygenases, such as prolyl
hydroxylases (PHDs), TET family 5-methylcytosine hydroxy-
lases, and JmjC domain-containing histone demethylases (Fig-
ueroa et al., 2010; Lu et al., 2012; Xu et al., 2011). While a
previous study reported hypoxia-mediated increases in 2HG
in the SF188 glioblastoma cell line, the authors suggested this
was a consequence of incomplete reductive carboxylation of
2OG by wild-type IDH to produce D2HG (Wise et al., 2011).
Here, we (1) demonstrate that hypoxia specifically increases
L2HG in a variety of cell types, (2) provide insight into the molec-
ular mechanisms of L2HG accumulation, (3) describe an impor-
tant role for L2HG metabolism in maintaining cellular and mito-
chondrial redox homeostasis, and (4) offer a mechanism for the
coordinated regulation of energy metabolism by L2HG through
inhibition of glycolysis and oxygen consumption. These obser-
vations provide important insights into the critical functional
role of L2HG metabolism in normal cell physiology.
RESULTS
Global Metabolic Reprogramming of Pulmonary
Vascular Cells in Response to Hypoxia
Hypoxia is a potent stimulus for pulmonary vascular remodel-
ing in patients with pulmonary hypertension, characterized
by smooth muscle and endothelial cell proliferation and meta-
bolic dysregulation (Cottrill and Chan, 2013). For this reason,
we initially measured levels of extracellular and intracellular
metabolites by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) in PAECs and PASMCs after 24 hr expo-
sure to 0.2% oxygen and compared those results with 21%
oxygen control samples. As expected, an increase in extra-
cellular lactate and a decrease in extracellular glucose were
observed in hypoxia-treated cells, consistent with increased
glycolytic flux (Figure S1). Similarly, hypoxia affected a broad292 Cell Metabolism 22, 291–303, August 4, 2015 ª2015 Elsevier Incrange of metabolic pathways (Figure 1A; Tables S1, S2, and
S3), including precursor biosynthesis, energy production
(glycolysis, TCA cycle, and electron transport chain), and
redox homeostasis (malate-aspartate shuttle, glycerol phos-
phate shuttle, nicotinamide metabolism, and glutathione meta-
bolism), as identified by metabolite set enrichment analysis (Xia
et al., 2009, 2012). Similar changes were observed in PAECs
and PASMCs.
A pathway topological analysis identified the TCA cycle as
among the most strongly modulated by hypoxia based on the
number of differentially regulated metabolites and the location
of these metabolites within the pathway (Xia et al., 2009, 2012)
(Figure 1A; Tables S1, S2, and S3). Consistent with decreased
TCA cycle flux, the levels of most TCA metabolites were
decreased by hypoxia, with the notable exception of 2OG (Fig-
ure 1A). Mitochondrial 2OG is produced in the TCA cycle by
oxidative decarboxylation of isocitrate by IDH2 and IDH3. 2-ox-
oglutarate then undergoes oxidative decarboxylation to succi-
nate by the 2OG dehydrogenase complex (OGDHC). Both
upstream TCA metabolites (aconitate, citrate, and isocitrate)
and downstream metabolites (succinate, fumarate, and malate)
are decreased or unchanged in hypoxia-treated cells, suggest-
ing that 2OG may be a reservoir of TCA carbon. Interestingly,
hypoxia increased levels of the reduced 2OG metabolite, 2HG,
in both cell types. Given the unknown role of D2HG and L2HG
in normal cell physiology, their demonstrated effects on 2OG-
dependent dioxygenases, and their connection to mitochondrial
redox shuttling, we sought to understand the role of 2HG meta-
bolism in the cellular response to hypoxia.
Hypoxia Increases L-2-Hydroxyglutarate
A targeted LC-MS/MS assay confirmed the hypoxia-mediated
increases in 2OG and 2HG in cell lysates of PAECs and PASMCs
(Figures 1B and 1C) and several other cell types, including lung
fibroblasts (LFs), immortalized cell lines (HEK293 and HepG2),
and mesenchymal stromal cells. This diversity of cell types sug-
gests that these metabolic changes are a common fundamental.
Figure 2. Hypoxia Preferentially Increases
the L Entantiomer of 2HG
(A) Extracted ion chromatograms (XIC) of under-
ivatized 2HG (purple) and derivatized enantio-
merically pure standards of D2HG (green), L2HG
(blue), or a racemic mixture (red). Chromatograms
are offset for clarity. The XIC of a derivatized cell
extract is also shown (black) with intensity values
on the right y axis.
(B) Fold change after hypoxia treatment of D2HG
and L2HG in derivatized cell extracts.
(C) Immunoblot of D2HGDH and L2HGDH levels in
LF treated with targeting siRNA compared to a
non-targeting control siRNA (siCTL).
(D) Total 2HG in cell extracts treated withD2HGDH
or L2HGDH siRNA.
(E) Immunoblot of LF cell extracts overexpressing
D2HGDH or L2HGDH.
(F) Total 2HG in LF overexpressing D2HGDH or
L2HGDH compared to vector control. Data are
mean ± SEM. See also Figure S2.feature of the hypoxia response. Basal intracellular concentra-
tions of 2OG and 2HG were approximately 0.4–2 mM and
0.05–0.24 mM, respectively, similar to previous estimates (Los-
man and Kaelin, 2013; MacKenzie et al., 2007; Matsunaga
et al., 2012). Hypoxia induced between a 1.5- to 2.5-fold in-
crease in 2OG and a 1.7- to 8.8-fold increase in 2HG depending
on the cell type. These increases vary inversely with oxygen ten-
sion (Figure 1D).
Cell extracts were derivatized with diacetyl-L-tartaric anhy-
dride (DATAN) to enable separation of 2HG enantiomers for
quantification by LC-MS/MS (Struys et al., 2004a) (Figures 2A
and 2B). Normoxic levels of D2HG and L2HG were similar;
however, L2HG preferentially increases with hypoxia in all cell
types examined except PASMC (Figure 2B). In PASMC, D2HG
and L2HG increased to a similar degree (1.5- ± 0.2- and 1.7- ±
0.2-fold, respectively; p = 0.45). Interestingly, the magnitude of
the L2HG increase was markedly greater in HEK cells compared
to other cell types.
As L2HG appears to be a common feature of the metabolic
response to hypoxia, LF were selected as the model cell line
for additional exploration of L2HG metabolism as they are pri-
mary cells that demonstrate robust increases in 2HG in response
to hypoxia and are likely more representative of characteristic
hypoxia responses than either PAECs or PASMCs. PAECs,
and endothelial cells generally, have a glycolytic phenotype,
which likely accounts for the low abundance of total 2HG in these
cells. PASMC proliferate under hypoxic conditions, demonstrate
smaller increases in L2HG, and were the only primary cellsCell Metabolism 22, 291–30studied with hypoxia-mediated increases
in D2HG. Thus, LF appeared to be the
most ideal model system for further anal-
ysis; however, many of the subsequent
results could also be extended to other
cell lines (as illustrated throughout this
report).
L2HG has a specific dehydrogenase,
L2HGDH, the only enzyme known to
metabolize L2HG. L2HGDH is a mito-chondrial protein that catalyzes the oxidation of L2HG to
2OG coupled to the reduction of FAD (Rzem et al., 2004,
2006; Topc¸u et al., 2004) (Figure 3A). Similarly, D2HG has a
specific mitochondrial dehydrogenase, D2HGDH, that cata-
lyzes its oxidation to 2OG and transfers electrons to FADH2
(Achouri et al., 2004; Struys et al., 2005). In confirmation of
the biochemical derivatization, LF treated with siRNA targeting
L2HGDH, but not D2HGDH, demonstrated a potentiation of
the hypoxia-mediated increase in total 2HG (Figures 2C and
2D). This was also observed in PAECs and in PASMCs despite
the results of the biochemical derivatization suggesting an in-
crease in both enantiomers in the PASMCs (Figures S2G and
S2H). L2HGDH silencing also increased 2HG levels in aerobic
conditions. In the complementary experiment, overexpression
of L2HGDH, but not D2HGDH, blocked the hypoxia-mediated
increase in 2HG (Figures 2E and 2F). 2HGDH knockdown and
overexpression had little effect on 2OG levels (Figures S2A
and S2B). Derivatization of LF cell extracts confirmed that
changes in total 2HG specifically reflect changes in L2HG in
these experimental conditions (Figures S2C–S2F). Notably,
siD2HGDH treatment did not result in significant changes in
D2HG, contrary to a previous study of MCF7 breast cancer
cells where siD2HGDH treatment induced a 4-fold increase
in total 2HG (enantiomeric quantification was not performed)
(Matsunaga et al., 2012). Together, these data demonstrate
a hypoxia-mediated increase in L2HG and no change in the
levels of (cancer-associated) D2HG in the metabolic response
of primary cells to hypoxia.3, August 4, 2015 ª2015 Elsevier Inc. 293
Figure 3. Potential Mechanisms of L2HG Accumulation in Hypoxia
(A) Enzymatic and cofactor requirements for L2HG metabolism.
(B and C) Intracellular 2OG (B) and 2HG (C) in normoxia and hypoxia measured after treatment with a cell-permeable 2OG analog, TFMB-2OG.
(D and E) 2OG (D) and 2HG (E) in cells treated with the OGDHC inhibitor KMV (20 mM) ± 0.2% oxygen.
(F) Correlation between 2OG and 2HG from experiments illustrated in (B)–(E).
(G) Immunoblot of MDH1 and MDH2 in siRNA-treated LF.
(H–J) 2OG (H), 2HG (I), and 2OG/2HG (J) in MDH knockdown cells.
(K) Relative changes in mRNA levels of 2HG metabolic enzymes in response to hypoxia.
(L) Immunoblot of LF cell lysates of proteins involved in L2HG metabolism.
(M) Intracellular malate determined by targeted LC-MS/MS.
(N) Cellular NADH/NAD+ determined by enzymatic cycling assay. Data are mean ± SEM. See also Figure S3.
294 Cell Metabolism 22, 291–303, August 4, 2015 ª2015 Elsevier Inc.
Mechanisms of L2HG Accumulation in Hypoxia
Given that 2OG is the only known substrate for L2HG synthesis,
we next examined whether increased intracellular 2OG could in-
crease L2HG in normoxia or potentiate the increase in hypoxia.
In LF treated for 24 hr with a cell-permeable analog of 2OG,
TFMB-2OG (MacKenzie et al., 2007), no increase in total 2HG
was observed in normoxia or hypoxia despite increased levels
of intracellular 2OG (Figures 3B and 3C). Mass isotopomer
studies of lymphoblasts derived from patients with D2HG or
L2HG aciduria suggest that the mitochondrial pool of 2OG is
reduced in 2HG synthesis (Struys et al., 2004b, 2007). We, there-
fore, treated cells with an inhibitor of OGDHC, a-keto-b-methyl-
valeric acid (KMV) (Patel, 1974). KMV increased 2OG and 2HG in
normoxia while potentiating the hypoxia-mediated increases in
both (Figures 3D and 3E). Indeed, the increases in 2HG were
highly correlated with increased 2OG in KMV-treated cells, while
no correlation was observed in cells treated with TFMB-2OG
(Figure 3F). These data suggest that compartmental metabolism
plays an important role in 2HG synthesis. OGDHC activity is
decreased by chronic hypoxia or oxidative stress, suggesting a
potential mechanism by which to account for the increases in
2OG and 2HG in hypoxia (Lai et al., 2003; Starkov, 2013; Tretter
and Adam-Vizi, 1999).
Malate dehydrogenases (MDH) 1 and 2 are the only enzymes
known to produce L2HG from the reduction of 2OG, which is
coupled to the oxidation of NADH (Rzem et al., 2007) (Figure 3A).
Both MDH enzymes catalyze the reversible oxidation of malate
to oxaloacetic acid (OAA) coupled to the reduction of NAD+.
MDH1 is localized to the cytoplasm where its kinetics favor
production of malate by the reduction of OAA. MDH2 is local-
ized to the mitochondria where production of OAA by the oxida-
tion of malate is favored. Together, MDH1 and MDH2 form
critical components of the malate-aspartate shuttle by which
cells transport electrons from the cytoplasmic NADH pool to
the mitochondrial NADH pool. MDH2 also catalyzes a key
step in the TCA cycle. 2-oxoglutarate reductase activity co-frac-
tionated with MDH activity in rat liver cytosolic and mitochon-
drial extracts, and purified MDH enzymes demonstrated
NADH-dependent reduction of 2OG to L2HG in vitro (Rzem
et al., 2007). To determine the role of MDH1 and MDH2 in hyp-
oxia-mediated 2HG accumulation, LF were treated with siRNA
targeting these enzymes separately and in combination (Figures
3G–3J). Knocking down either MDH enzyme potentiated the
hypoxia-mediated increase in 2OG and impaired the hypoxia-
mediated increase in 2HG, resulting in an increase in the
substrate/product (i.e., 2OG/2HG) ratio. These findings were
confirmed in HEK293 cells (Figure 3S) and were similar to re-
sults from mouse embryonic fibroblasts isolated from l2hgdh/
mice (Rzem et al., 2015). This supports the role of both MDH
enzymes in the synthesis of L2HG from 2OG. No evidence of
increased MDH enzyme expression or protein was observed
(Figures 3K and 3L). L2HG production may be favored in hypox-
ia by decreased competition by malate for MDH2 owing to a
reduction of the concentration of this metabolite (Figure 3M)
and an increase in cellular NADH (Figure 3N).
In addition to increased synthesis, hypoxia caused a 50%
reduction in L2HGDH expression (Figure 3K) associated with
a small reduction in L2HGDH protein (Figure 3L), sug-
gesting a role for decreased oxidation of L2HG to 2OG in hyp-Celoxia. Comparatively smaller hypoxia-mediated decreases in
D2HGDH expression and protein were observed (Figures 3K
and 3L).
HIF1a Is Sufficient but Not Necessary for 2HG
Accumulation
HIF1a and HIF2a are constitutively expressed and degraded un-
der normoxic conditions through the combined actions of PHD
and VHL, an E3 ubiquitin ligase that recognizes hydroxylated
HIF and targets it for proteasomal degradation (Kaelin and Rat-
cliffe, 2008). To test the role of HIF in 2HG metabolism, LF
were treated with siRNA targeting VHL to prevent the degrada-
tion of HIF1a and HIF2a in normoxic conditions (Figures 4A–
4C). Consistent with normoxic HIF activity, siVHL-treated cells
had increased expression of the HIF1a target GLUT1 and
HIF2a target SERPINE1 (Figure 4B). These cells also demon-
strated an increase in 2OG and 2HG in normoxia, suggesting
that HIF stabilization is sufficient for these metabolic changes
(Figure 4C). Notably, VHL silencing had no impact on the expres-
sion of L2HGDH (Figure 4B).
To test whether HIF is necessary for these metabolic changes
in hypoxia, cells were treated with siRNA targeting HIF1a and
HIF2a alone or in combination (Figures 4D–4I). Surprisingly, si-
HIF1 potentiated the hypoxia-mediated increases in 2OG and
2HG despite blunting the hypoxia-mediated increase in GLUT1
mRNA (Figures 4E, 4G, and 4H). Treatment with siHIF2 had no ef-
fect on 2OGor 2HG levels despite blunting the hypoxia-mediated
increase in SERPINE1 expression (Figures 4F, 4G, and 4H).
Derivatization with DATAN confirmed that L2HG is the enan-
tiomer increased by hypoxia in the HIF1a knockdown (Figures
S4A andS4B). Elevations in succinate andmalatewere observed
in siHIF1-treated cells in hypoxia, suggesting that persistent TCA
carbon flux in the absence of HIF1a activation accounts for the
potentiation of the hypoxia-mediated increase in L2HG (Figures
S4C and S4D). Silencing of HIF had little impact on the hypox-
ia-mediated decrease in L2HGDHmRNA (Figure 4I). Thus, while
HIF stabilization and activation of a hypoxia-like gene expression
program are associated with increases in 2OG and L2HG in nor-
moxia, these data suggest an alternativemechanism, not depen-
dent onHIF, that causes thesemetabolic changes in hypoxia. The
discrepancies between L2HGDH expression and 2HG concen-
tration support a stronger role for an alternative mechanism to
decreased L2HGDHactivity (e.g., OGDHC inhibition or increased
mitochondrial NADH) causing L2HG accumulation in hypoxia.
In contrast to LF, VHL knockdown in HEK cells did not result in
normoxic increases in 2HG or 2OG (Figures S4E and S4F). Addi-
tionally, siHIF2 blunted the hypoxia-mediated increases in HEK,
while siHIF1 had little effect (Figures S4G–S4I).
2HGDH Knockdown Activates HIF1a Independent of
2HG Levels
Both L2HG and D2HG have been shown to inhibit the function of
2OG-dependent dioxygenases, like PHD (Xu et al., 2011),
although D2HG has also been shown to activate PHD (Koivunen
et al., 2012; Losman et al., 2013). Thus, we hypothesized that
hypoxia-mediated increases in L2HG may potentiate HIF1a
stabilization through PHD inhibition. To test this, LF were treated
with siRNA targeting D2HGDH and L2HGDH. The expression
of HIF1a target genes GLUT1 and LDHA were measured byl Metabolism 22, 291–303, August 4, 2015 ª2015 Elsevier Inc. 295
Figure 4. Role of HIF in 2HG Metabolism
(A) Immunoblot of LF treated with siRNA targeting VHL mRNA compared to siCTL demonstrating stabilization of HIF1a and HIF2a in normoxia.
(B) Normoxic stabilization of HIF1a and HIF2a increases GLUT1 and SERPINE1 mRNA, but has no effect on L2HGDH mRNA.
(C) HIF stabilization through VHL knockdown is sufficient to increase 2HG and 2OG in normoxia.
(D) Immunoblot demonstrating effective knockdown of HIF1a and HIF2a in normoxia and hypoxia.
(E) Silencing HIF1a blunts the hypoxia-mediated increase in GLUT1 expression.
(F) Silencing HIF2a blunts the hypoxia-mediated increase in SERPINE1 expression.
(G and H) 2HG and 2OG in cells treated with HIF siRNA in normoxia and hypoxia.
(I) Levels of L2HGDH mRNA in cells treated with siRNA targeting hypoxia-regulated transcription factors. Data are mean ± SEM. See also Figure S4.RT-qPCR (Figures 5A and 5B), and HIF1a protein was measured
by immunoblot (Figures 5C and 5D). Under normoxic conditions,
both siD2HGDH and siL2HGDH treatment increased HIF1a pro-
tein and target gene expression, and these changes were poten-
tiated by hypoxia. These findings were similar in PAECs and
PASMCs treated with siRNA targeted to the 2HGDH enzymes
(Figures S5A–S5E), although PASMC did not demonstrate
changes in LDHA expression in response to siRNA (Figure S5E).
By contrast, 2HGDH overexpression had no effect on GLUT1
or LDHA mRNA (Figures 5E and 5F). This finding, together with
the observation that D2HGDH knockdown had no impact on
cellular 2HG (Figures 2D and S2C), suggested an alternative
mechanism of HIF1a stabilization independent of direct PHD
inhibition by 2HG. Superoxide through its metabolism to H2O2
is a known activator of HIF (Go¨rlach and Kietzmann, 2007).
As D2HGDH and L2HGDH are localized to the inner mitochon-
drial membrane, we measured whether 2HGDH suppression296 Cell Metabolism 22, 291–303, August 4, 2015 ª2015 Elsevier Incincreased superoxide production as a potential mechanism of
HIF1a activation. Both siD2HGDH and siL2HGDH increased
mitochondrial superoxide measured by MitoSOX (Figures 5G
and 5H) in a pattern similar to the changes in HIF1a target
gene expression. While treatment with N-acetylcysteine (NAC)
had no impact on MitoSOX fluorescence or HIF1a target gene
expression under normoxia, it did decrease the signal under
hypoxia (Figures S5F–S5H). These data support an alternative
mechanism for HIF stabilization beyond direct PHD inhibition
by 2HG. While the correlation with superoxide production is
compelling, these data suggest ROS generation is not the only
mechanism linking 2HGDH silencing and HIF activation.
L2HG Metabolism Contributes to Cellular Redox
Homeostasis
The metabolites 2OG and L2HG form a redox couple linked to
NADH/NAD+ and FADH2/FAD.Moreover, both 2HG enantiomers.
Figure 5. D2HGDH and L2HGDH Knock-
down Activate HIF Target Gene Expression
(A, B, E, and F) Expression of HIF target genes,
GLUT1 ([A] and [E]) and LDHA ([B] and [F]) in LF
treated with siD2HGDH and siL2HGDH ([A] and
[B]) or D2HGDH and L2HGDH ([E] and [F]).
(C) Representative immunoblot demonstrating
normoxic HIF1a stabilization by siD2HGDH and
siL2HGDH.
(D) Quantification of HIF1a densitometry.
(G) Representative micrographs of MitoSOX-
stained cells. Images were inverted and leveled for
presentation. Scale bar is 20 mm.
(H) Quantification of MitoSOX staining. Data are
mean ± SEM. See also Figure S5.appear to be biochemical cul-de-sacs that do not participate in
other reactions beyond oxidation back to 2OG. These features
raise the possibility that 2HG may provide cells with a reservoir
of reducing equivalents and that 2HG-2OG interconversions
may buffer cellular redox potential.
To examine this, whole-cell NADH/NAD+ ratios were mea-
sured by an enzymatic cycling assay in 2HGDH knockdown
or overexpressing cells (Figures 6A and 6B). We found
that increased cellular L2HG increases NADH/NAD+. To test if
exogenous L2HG could also increase cellular NADH/NAD+, LFCell Metabolism 22, 291–30expressing a genetically encoded fluores-
cence sensor of NADH/NAD+ in situ,
SoNar (Zhao et al., 2015), were treated
with permeable trifluoromethylbenzyl
ester (TFMB) derivatives of 2OG, D2HG,
and L2HG (Losman et al., 2013; MacKen-
zie et al., 2007) (Figures 6C and S6). Both
D2HG and L2HG derivatives increased
the fluorescence ratio, indicating an in-
crease in NADH/NAD+, while the perme-
able 2OG compound had the opposite
effect. These increases in NADH/NAD+
were dose dependent in HEK cells (Fig-
ure S6). This evidence lends support to
the hypothesis that 2HG is a source of
cellular reducing equivalents.
L2HGDH Regulates Bioenergetic
Metabolic Pathways
The TCA cycle and glycolysis are the pri-
mary pathways producing NADH in the
mitochondrion and cytoplasm, respec-
tively. Similar to succinate dehydroge-
nase (Complex II), both D2HGDH and
L2HGDH are mitochondrial flavoproteins
that couple electron transfer from 2HG to
FAD and subsequently to coenzyme Q.
One mechanism leading to NADH accu-
mulation in siRNA-treated cells may be
impaired electron transport. To test this
hypothesis, siRNA-treated LF were sub-
jected to a mitochondrial stress assay,
where oxygen consumption rate (OCR) ismeasured as cells are treated sequentially with oligomycin to
inhibit ATP synthesis, FCCP to collapse the inner membrane
potential (DJm), and antimycin A plus rotenone to inhibit all
flux through the respiratory chain (Figures 7A and 7B). Compared
to siCTL, siL2HGDH decreased basal OCR and both siD2HGDH
and siL2HGDH decreased maximal OCR assessed after FCCP
treatment. No difference in mitochondrial coupling efficiency
or non-mitochondrial OCR was observed. To explore further
the role of 2HG metabolism under hypoxic conditions, siRNA-
treated cells were labeled with tetramethylrhodamine methyl3, August 4, 2015 ª2015 Elsevier Inc. 297
Figure 6. 2HG Metabolism Is Coupled to Cellular Redox State
(A and B) NADH/NAD+ ratio determined by enzymatic cycling assay in LF treated with siRNA targeting D2HGDH or L2HGDH expression (A) or overexpressing
D2HGDH or L2HGDH (B).
(C) F420/F485 fluorescence ratio, corresponding to cytoplasmic NADH/NAD
+, in LF treated with permeable analogs of 2OG, D2HG, and L2HG (500 mM) at time
0 normalized to the fluorescence ratio of untreated cells. Data are mean ± SEM. See also Figure S6.ester (TMRM), a fluorescent indicator of DJm. While no differ-
ences were observed in normoxia, siD2HGDH and siL2HGDH
reversed the hypoxia-mediated increase in DJm (Figures 7C
and 7D). These data are consistent with theOCRmeasurements,
and, together, indicate that both 2HGDH enzymes contribute to
the generation of the mitochondrial membrane potential under
stressed (e.g., FCCP or hypoxia) conditions.
As glycolysis is a major determinant of cytoplasmic reducing
potential under hypoxic conditions, we next measured the effect
of 2HGDH knockdown on glycolytic flux by measuring the extra-
cellular acidification rate (ECAR) in response to glucose and oli-
gomycin (Wu et al., 2007). Cells treated with siL2HGDH had a
modest decrease in basal ECAR and a marked decrease in
oligomycin-stimulated ECAR compared to siCTL-treated cells
(Figures 7E and 7F). In contrast, siD2HGDH increased glycolytic
capacity while having no effect on basal glycolytic flux. To test if
exogenous L2HG could inhibit oligomycin-stimulated ECAR, LF
were treated with the cell-permeable 2HG analogs. Both TFMB-
D2HG and TFMB-L2HG reduced glycolytic capacity by 12% and
19%, respectively, compared to vehicle (Figure 7G). These find-
ings were confirmed with alternative siRNA sequences targeting
the 2HGDH enzymes (Figure S7A). PAECs treated with siRNA
targeting the 2HGDH enzymes recapitulated the findings in
LF, while PASMC demonstrated only inhibition of ECAR by
siL2HGDH (Figures S7B andS7C). The latter finding is consistent
with the inability of siD2HGDH to increase LDHA expression in
PASMC (Figure S5E). NAC had little impact on oligomycin-stim-
ulated ECAR in siD2HGDH-treated cells while further reducing
glycolytic flux in siL2HGDH-treated cells (Figure S7D).
DISCUSSION
Hypoxia is an important stimulus that requiresmetabolic adapta-
tion to sustain energy production; mitigate ROS production;
maintain cellular redox homeostasis; and, in some cases, facili-
tate cell proliferation. Much of our understanding of the cellular
response to hypoxia is derived from studies of the HIF1a tran-
scriptional program or of metabolic flux in malignant cell lines.
The goal of this study was to identify novel features of the hypox-
ia response in primary cultured cells. Here, we demonstrate that
hypoxia specifically and dose-dependently induces the accumu-298 Cell Metabolism 22, 291–303, August 4, 2015 ª2015 Elsevier Inclation of L2HG in a variety of cell types and that L2HG meta-
bolism is closely coupled to cellular redox state and energy
metabolism through inhibition of glycolytic flux and oxygen
consumption.
These studies confirm that theMDH enzymes are likely the pri-
mary enzymes responsible for L2HG generation in hypoxia. The
most important mechanism for increased L2HG synthesis is
likely related to increased substrate (2OG andNADH) availability.
Hypoxia lowers L2HGDH, although siVHL treatment increased
2OG and 2HG in normoxia without affecting L2HGDH mRNA.
The contrasting effects of VHL and HIF knockdown in LF and
HEK cells specifically suggest different biochemical mecha-
nisms leading to L2HG accumulation. MDH knockdown inhibited
L2HG production in both cell types. In LF, VHL knockdown could
partially recapitulate the hypoxia-mediated changes under
normoxia, while HEK cells were insensitive to siVHL despite
demonstrable HIF1a stabilization. Indeed, HEK cells were also
unaffected by siHIF1 in hypoxia, while this treatment markedly
enhanced L2HG production in LF under hypoxia. Previous
studies have highlighted the importance of glutaminolysis in ma-
lignant cells under hypoxic conditions (Gameiro et al., 2013;
Scott et al., 2011; Wise et al., 2011). We speculate that the pri-
mary carbon source for L2HG production in LF is glycolysis,
while in HEK the primary carbon source may be glutaminolysis,
thereby accounting for the differential consequences of HIF
knockdown.
In addition to hypoxia, mutations in CYTB in osteosarcoma
cells (Complex III deficiency), and fumarate hydratase deficiency
in renal carcinoma cells, and Complex I inhibition with rotenone
increase L2HG (Mullen et al., 2014; Worth et al., 2015). A metab-
olomics study of urinary organic acids in children with electron
transport chain disorders also identified increases in total
2HG, presumed by the authors to be L2HG (Reinecke et al.,
2012). These observations indicate that L2HG increases in
response to mitochondrial reductive stress caused by respira-
tory chain or TCA dysfunction. All of these perturbations in-
crease mitochondrial NADH, and likely 2OG, thereby providing
the substrates for L2HG production. Given that the only known
metabolic fate of L2HG is oxidation to 2OG, we considered
that L2HG might serve as a sink for mitochondrial reducing
equivalents under conditions of reductive stress. To test this,.
Figure 7. D2HGDH and L2HGDH Silencing Affects Oxidative Phosphorylation and Glycolysis
(A) OCR of LF treated with siRNA targeting D2HGDH or L2HGDH after treatment with the indicated compounds (Oligo, oligomycin; AMA, antimycin A).
(B) Summarized data from (A).
(C) Representative micrographs of TMRM-stained LF. Images were inverted and leveled for presentation. Scale bar is 20 mm.
(D) Quantification of TMRM staining in normoxia and hypoxia in siRNA-treated LF.
(E) ECAR of LF treated with siRNA targeting D2HGDH or L2HGDH before and after treatment with oligomycin to measure glycolytic capacity (2DG, 2-deoxy-
glucose).
(F) Summarized data from (E).
(G) Cell-permeable analogs of D2HG and L2HG inhibit oligomycin-stimulated ECAR. Data are mean ± SEM. See also Figure S7.
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we measured whole-cell NADH/NAD+ and found that this ratio
varied directly with L2HG (and inversely with L2HGDH activity)
in hypoxia. Results from the intracellular fluorescent NADH/
NAD+ sensor indicate that exogenously administered L2HG
can transfer electrons to NAD+, consistent with this potential
role for L2HG as an electron sink (and carrier). Together, these
data raise the question as to the mechanism of L2HG oxidation,
particularly in the context of L2HGDH knockdown, as this is the
only known enzyme with L2HG oxidase activity.
To examine the impact of L2HG redox shuttling on mitochon-
drial reducing potential, we measured OCR and TMRM fluores-
cence. These studies suggest that L2HGDH contributes to the
generation of DJm, as shown by reduced FCCP-stimulated
OCR in normoxia and decreased TMRM fluorescence in hypox-
ia. The data also suggest that L2HGDH downregulation in hypox-
ia may mitigate mitochondrial membrane hyperpolarization and
attendant ROS generation. Indeed, siL2HGDH blunted the hyp-
oxia-mediated increase in MitoSOX fluorescence accounting
for elevated superoxide production in normoxia. Previous work
has shown no direct effect of L2HG on electron flux through
the respiratory chain in rat cortical homogenates and striated
muscle cells (da Silva et al., 2002; Latini et al., 2005); however,
L2HG was able to decrease the respiratory control ratio (RCR),
suggesting uncoupling of electron transport from ATP produc-
tion (Latini et al., 2005). Our data from whole cells may also be
consistent with a decrease in RCR based on the reduction in
FCCP-stimulated OCR (Brand and Nicholls, 2011); however,
additional studies are necessary to clarify if this is a conse-
quence of too much L2HG (and uncoupling) or too little electron
transport via L2HGDH (and decreased DJm).
Perhaps the most striking finding in the present work is the
marked impact of L2HGDH knockdown on glycolytic flux and oli-
gomycin-stimulated glycolytic capacity (25% and 35% reduc-
tions, respectively). This observation supports the compelling
hypothesis that L2HG serves to couple the two main compo-
nents of cellular NADH production, glycolysis and the TCA cycle,
through a redox-sensitive mechanism. As L2HG accumulates in
response to reductive stress, it initiates a negative feedback loop
to limit additional NADH production by glycolysis. Whether this
occurs as a consequence of direct inhibition of glycolytic en-
zymes by L2HG or through accumulation of cytoplasmic NADH
remains to be determined. The observation that cell-permeable
analogs of both D2HG and L2HG had similar effects on oligo-
mycin-stimulated ECAR may support the latter hypothesis.
Together, these data provide evidence that L2HG, a mitochon-
drial metabolite, inhibits cytoplasmic NADH production to coor-
dinate cellular redox homeostasis.
Recently, investigators have described an l2hgdh/ mouse
characterized by neurological deficits (Rzem et al., 2015). A
limited metabolomics analysis identified markedly increased
concentrations of lysine and arginine associated with decreases
in saccharopine, glutamine, and glutamate in the brains of adult
l2hgdh/ mice. L2HG inhibits lysine/2OG reductases, which
converts lysine to saccharopine, in one pathway of lysine degra-
dation. A role for L2HG inhibition of lysine/2OG reductases in
hypoxia is not clear from our data, as lysine levels decreased
in both PAECs and PASMCs. Interestingly, the lysine degrada-
tion pathway was identified in our (network-based) analyses,
and lysine metabolism is a source of NADH production through300 Cell Metabolism 22, 291–303, August 4, 2015 ª2015 Elsevier Incthe functions of sacchariopine dehydrogenase and a-aminoadi-
pate semialdehyde dehydrogenase.
In contrast to L2HGDH silencing,D2HGDH silencing increased
glycolytic capacity, presumably as a consequence of HIF1a
activation and upregulation of glucose transporters and glyco-
lytic genes.While the correlation between superoxide production
and HIF stabilization suggested one potential mechanism linking
these observations, NAC was unable to abrogate the changes in
HIF target geneexpressionor glycolytic flux in the2HGDHknock-
down cells. While studies have shown that both D2HG and L2HG
can inhibit PHD (Figueroa et al., 2010; Lu et al., 2012; Xu et al.,
2011), the observations that HIF is stabilized in siD2HGDH-
treated cells despite no change in intracellular D2HG levels and
that blocking L2HG accumulation in hypoxia through L2HGDH
overexpression has no effect on HIF target gene expression
argue against this mechanism. The regulation of HIF is complex,
and a variety ofmechanisms have been implicated in its stabiliza-
tion, includingmicroRNA, other post-translationalmodifications,
and intracellular signaling cascades (e.g., ERK and AKT), in addi-
tion to ROS and PHD inhibition (Movafagh et al., 2015; Yee Koh
et al., 2008). Indeed, the incompletely understood etiology of
HIF activation under aerobic conditions is of critical importance
to our understanding of the pathogenesis of cancer and pulmo-
nary vascular disease.
Manipulations of D2HG metabolism resulted in similar effects
on NADH/NAD+, mitochondrial superoxide production, and
OCR as manipulations of L2HG metabolism, which may be a
consequence of similarities in the enzymology of D2HGDH and
L2HGDH and the structural similarities of D2HG and L2HG.
Importantly, these data clearly indicate that hypoxia affects
L2HG metabolism exclusively, indicating that exquisite enantio-
meric specificity is provided by the biology of the hypoxia
response. PASMC were the only cell type in which hypoxia-
mediated increases in D2HG were observed by biochemical
derivatization; however, siD2HGDH was unable to potentiate
the hypoxia-mediated increases in total 2HG in these cells.
Given that PASMC proliferate in response to hypoxia, one inter-
esting hypothesis is that the D2HG represents incomplete reduc-
tive carboxylation by IDH in these cells as has been observed in a
variety of cancer cell lines (Gameiro et al., 2013; Scott et al.,
2011; Wise et al., 2011).
While D2HG is a so-called ‘‘oncometabolite’’ produced bymu-
tations in IDH associated with an increasing number of human
malignancies (Cairns and Mak, 2013), these data reinforce the
notion that D2HG and L2HG are separate and distinct metabo-
lites with unique effects on metabolic regulation (Struys, 2013).
Given the prominence of regional hypoxia in tumor biology, this
work also highlights the importance of enantiomeric character-
ization of 2HG elevations, particularly as L2HG has recently
been identified in association with renal cell carcinoma tissues,
many of which contained VHL mutations (Shim et al., 2014).
L2HGDH is found in bacteria, plants, and animals (Engqvist
et al., 2014). Despite its evolutionary conservation, the only
ascribed role for this enzyme is the recovery of 2OG mistakenly
reduced by non-specific enzymatic activity (Kalliri et al., 2008;
Rzem et al., 2007). Indeed, L2HG aciduria, caused by mutations
in L2HGDH, has been described as a ‘‘disorder of metabolite
repair’’ (Rzem et al., 2007). In this work, we propose that L2HG
serves an important role in the regulation of cellular redox.
homeostasis and cellular energy metabolism through its regula-
tion of glycolysis and oxidative phosphorylation. Future studies
will focus on the relationships between L2HG, glycolytic en-
zymes and intermediates, and the regulation of compartmental
NADH/NAD+ to test this hypothesis. Importantly, our data
show that L2HG is much more sensitive to metabolic perturba-
tions and hypoxia than D2HG in the cells studied here and may
play a critical role in the adaptive response to hypoxia.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
Primary human PAECs, PASMCs, LFs, and mesenchymal stem cells (MSCs)
were cultured in their respective growth media without antibiotics (Lonza).
HEK293 and HepG2 cells were cultured in high-glucose DMEM (Life Technol-
ogies) supplemented with 10% FBS (Mediatech).
Hypoxia Treatment
Cells were placed in a modular incubator chamber (Billups-Rothenberg)
flushed with 100 L of a gas mixture containing 0.2% or 2% O2, 5% CO2, and
balanced with N2 (Airgas) then incubated at 37
C for 24 hr.
Targeted LC-MS/MS
Metabolites were extracted in cold 80% methanol. Prior to scraping, [13C4]-
2OG (Cambridge Isotope Laboratories) was added as an internal standard
(ISTD). Metabolites were separated using a ZIC-HILIC stationary phase
(150 mm3 2.1 mm3 3.5 mm; Merck). The MS parameters were optimized us-
ing a 2HG standard solution. Monitored mass transitions were 147 / 129
(2HG, Rt 10.3 min), 145 /101 (2OG, Rt 10.1 min), 133 / 115 (malate, Rt
10.6 min), 115 /73 + 99 (succinate, Rt 4.7 min), and 149/ 105 (ISTD, Rt
10.1 min). Retention time windows were confirmed by the analysis of neat
andmatrix-spiked standards. Peak areaswere quantified by Xcalibur Software
(Thermo) andmanually reviewed. Concentrations were determined by interpo-
lating the peak area ratio of analyte to ISTD from a standard curve (0.1–10 mM
neat standards). Concentrations were normalized to cell count from plates of
cells treated in parallel.
Quantification of 2HG Enantiomers
Metabolite extracts were derivatized with diacetyl-L-tartaric anhydride
(DATAN) using an adaptation of a previously described method (Struys
et al., 2004a). In-source fragmentation of the derivatized species was
observed, and the mass transition for 2HG, 147 / 129, was monitored.
The derivatization reaction proceeded to completion, and 2HG and
DATAN-2HG were well resolved chromatographically with an Rt shift
from 10.5 min (D2HG) to 11.4 (L2HG) (Figure 2A). Standard solutions of
enantiomerically pure D2HG and L2HG were derivatized with 100 mM
lactate as a catalyst in parallel to generate a standard curve (0–2 mM). Con-
centrations of D2HG and L2HG were normalized to cell count.
NADH/NAD+ Enzymatic Assay
Cellular NAD+ and NADH were measured using an adaptation of a previously
published enzymatic fluorimetric cycling assay (Umemura and Kimura, 2005;
Zhu and Rand, 2012).
ROS and DJm Measurements
Cells were stained with 5 mMMitoSOX (Life Technologies) or TMRM (2 nM) for
30 min at 37C. Ten random images per well were recorded using a Nikon
TE2000 epifluorescent microscope. Mean cell fluorescence intensity for
each image was determined using CellProfiler (Kamentsky et al., 2011). For
presentation, themicrographs were inverted and leveled using the same range
for all images.
Extracellular Flux Analyses
Cells were treated with siRNA 48 hr prior to the experiment and seeded at a
density of 25,000 cells per well 24 hr prior to the assay. NAC (10 mM) was
added at the time of seeding in the assay plate. OCR and ECAR wereCelmeasured on an XF24 or XFe24 Analyzer (Seahorse Biosciences). Mitochon-
drial and glycolytic stress assays were performed according to the manufac-
turer’s protocols. Permeable compounds were injected following oligomycin
in a standard glycolysis stress assay, and ECAR was measured after 4 hr
and prior to injection of 2-deoxyglucose. OCR and ECAR were normalized to
cell count measured after assay completion.
Statistical Analyses
Calculations were performedwith GraphPad Prism 6. Data are the mean ± SEM
of a minimum of three biological replicates. Data were analyzed by paired
Student’s t test, one-way ANOVA, or two-way ANOVA, as appropriate. The
significance threshold used was p < 0.05. Same treatment normoxia-hypoxia
differences are indicated by y, and same oxygen treatment-control differences
are indicated by *.
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